Literature DB >> 23778568

Risk factors for BK virus infection in the era of therapeutic drug monitoring.

Claire Borni-Duval1, Sophie Caillard, Jérôme Olagne, Peggy Perrin, Laura Braun-Parvez, Françoise Heibel, Bruno Moulin.   

Abstract

BACKGROUND: Overimmunosuppression is a widely recognized risk factor for BK virus (BKV) infection, particularly with the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids. Nevertheless, the exact impact of exposure to tacrolimus and MMF is not well understood.
METHODS: We examined 240 kidney recipients between 2006 and 2008. BKV was monitored every 2 months in the urine or blood. A kidney biopsy was performed when viremia exceeded 10 copies/mL.
RESULTS: Ninety-five (40%) patients had sustained viruria, 48 (20%) sustained viremia, and 17 (7%) biopsy-proven polyomavirus-associated nephropathy. The mean time-to-occurrence was 7.6, 7.9, and 9.7 months for viruria, viremia, and polyomavirus-associated nephropathy. Risk factors associated with BKV infection in univariate analyses were retransplantation, panel-reactive antibody more than 0%, cytomegalovirus D+/R-, cold ischemia time, delayed graft function, induction with antithymocyte globulins, acute rejection before month 3 (M3), tacrolimus trough levels more than 10 ng/mL, and M3 AUC0-12 hr more than 50 hr mg/L. Multivariate analyses showed that cytomegalovirus D+/R- (adjusted hazard ratio [AHR], 2.03; P=0.05), acute rejection (AHR, 5.4; P<0.001), and mycophenolic acid AUC0-12 hr more than 50 hr mg/L (AHR, 3.6; P=0.001) were risk factors for BKV.
CONCLUSIONS: This study identified a link between a state of increased immunosuppression and BKV infection, especially in patients with higher MMF exposure and elevated tacrolimus trough levels at M3.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23778568     DOI: 10.1097/TP.0b013e3182921995

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  28 in total

Review 1.  The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy.

Authors:  Guido Filler; Ana Catalina Alvarez-Elías; Christopher McIntyre; Mara Medeiros
Journal:  Pediatr Nephrol       Date:  2016-02-26       Impact factor: 3.714

2.  Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement.

Authors:  Morgane Solis; Mariam Meddeb; Charlotte Sueur; Pilar Domingo-Calap; Eric Soulier; Angeline Chabaud; Peggy Perrin; Bruno Moulin; Seiamak Bahram; Françoise Stoll-Keller; Sophie Caillard; Heidi Barth; Samira Fafi-Kremer
Journal:  J Clin Microbiol       Date:  2015-10-14       Impact factor: 5.948

3.  Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients.

Authors:  Aurélie Velay; Morgane Solis; Ilies Benotmane; Pierre Gantner; Eric Soulier; Bruno Moulin; Sophie Caillard; Samira Fafi-Kremer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 4.  BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.

Authors:  George R Ambalathingal; Ross S Francis; Mark J Smyth; Corey Smith; Rajiv Khanna
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

5.  Toward standardization of BK virus monitoring: evaluation of the BK virus R-gene kit for quantification of BK viral load in urine, whole-blood, and plasma specimens.

Authors:  Charlotte Sueur; Morgane Solis; Mariam Meddeb; Eric Soulier; Pilar Domingo-Calap; Quentin Lepiller; Rachel Freitag; Seiamak Bahram; Sophie Caillard; Heidi Barth; Françoise Stoll-Keller; Samira Fafi-Kremer
Journal:  J Clin Microbiol       Date:  2014-10-08       Impact factor: 5.948

6.  Development and evaluation of a BK polyomavirus serotyping assay using Luminex technology.

Authors:  Herman F Wunderink; Caroline S de Brouwer; Els van der Meijden; Diana V Pastrana; Aloysius C M Kroes; Christopher B Buck; Mariet C W Feltkamp
Journal:  J Clin Virol       Date:  2018-12-01       Impact factor: 3.168

Review 7.  Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 8.  Role of Virus-Specific T Cell Therapy for Cytomegalovirus and BK Infections in Kidney Transplant Recipients.

Authors:  Sandesh Parajuli; Margaret Jorgenson; Ross O Meyers; Arjang Djamali; Jacques Galipeau
Journal:  Kidney360       Date:  2021-03-26

9.  Deceased-Donor Acute Kidney Injury and BK Polyomavirus in Kidney Transplant Recipients.

Authors:  Isaac E Hall; Peter Philip Reese; Sherry G Mansour; Sumit Mohan; Yaqi Jia; Heather R Thiessen-Philbrook; Daniel C Brennan; Mona D Doshi; Thangamani Muthukumar; Enver Akalin; Meera Nair Harhay; Bernd Schröppel; Pooja Singh; Francis L Weng; Jonathan S Bromberg; Chirag R Parikh
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-10       Impact factor: 8.237

Review 10.  BK Polyomavirus Nephropathy in Kidney Transplantation: Balancing Rejection and Infection.

Authors:  Chia-Lin Shen; Bo-Sheng Wu; Tse-Jen Lien; An-Hang Yang; Chih-Yu Yang
Journal:  Viruses       Date:  2021-03-16       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.